Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1995 1
2002 2
2004 1
2005 3
2006 1
2007 2
2008 5
2009 5
2010 2
2011 6
2012 13
2013 12
2014 5
2015 8
2016 5
2017 3
2018 3
2019 3
2020 4
2021 5
2022 6
2023 1
2024 2
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

84 results

Results by year

Filters applied: . Clear all
Page 1
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M; OPTIMISMM trial investigators. Richardson PG, et al. Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13. Lancet Oncol. 2019. PMID: 31097405 Clinical Trial.
Iron-overload myopathy.
Munoz J, Ferrari N, Kuriakose P. Munoz J, et al. Among authors: kuriakose p. Int J Hematol. 2011 Dec;94(6):503-4. doi: 10.1007/s12185-011-0961-1. Epub 2011 Nov 3. Int J Hematol. 2011. PMID: 22045307 No abstract available.
Unexplained macrocytosis.
Younes M, Dagher GA, Dulanto JV, Njeim M, Kuriakose P. Younes M, et al. Among authors: kuriakose p. South Med J. 2013 Feb;106(2):121-5. doi: 10.1097/SMJ.0b013e3182824cdf. South Med J. 2013. PMID: 23380746
Thalidomide-induced severe hepatotoxicity.
Dabak V, Kuriakose P. Dabak V, et al. Among authors: kuriakose p. Cancer Chemother Pharmacol. 2009 Mar;63(4):583-5. doi: 10.1007/s00280-008-0891-7. Epub 2008 Dec 16. Cancer Chemother Pharmacol. 2009. PMID: 19083237 No abstract available.
Antibiotic-refractory sinusitis.
Munoz J, Kuriakose P. Munoz J, et al. Among authors: kuriakose p. JAMA. 2012 Dec 12;308(22):2399-400. doi: 10.1001/jama.2012.91077. JAMA. 2012. PMID: 23232896 No abstract available.
Targeted therapy for hematologic malignancies.
Kuriakose P. Kuriakose P. Cancer Control. 2005 Apr;12(2):82-90. doi: 10.1177/107327480501200203. Cancer Control. 2005. PMID: 15855891 Free article. Review.
Liver transplantation in the haemophilia patient.
Lambing A, Kuriakose P, Kachalsky E. Lambing A, et al. Among authors: kuriakose p. Haemophilia. 2012 Mar;18(2):300-3. doi: 10.1111/j.1365-2516.2011.02631.x. Epub 2011 Aug 19. Haemophilia. 2012. PMID: 21854510 Review.
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksaç M, Legieć W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos MV, Špička I, Lazaroiu M, Berdeja J, Kaufman JL, Jou YM, Ganetsky A, Popa McKiver M, Lonial S, Weisel K; ELOQUENT-1 investigators. Dimopoulos MA, et al. Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9. Lancet Haematol. 2022. PMID: 35550060 Free article. Clinical Trial.
84 results